Search results
Results From The WOW.Com Content Network
Researchers have identified a new biomarker for Alzheimer's disease, which could help doctors diagnose it before symptoms start showing.
The idea of a collaboration between public institutions and private pharmaceutical companies to fund a large biomarker project to study AD and to speed up progress toward effective treatments for the disease was conceived at the beginning of the millennium by Neil S. Buckholz at the National Institute on Aging (NIA) and Dr. William Potter, at Eli Lilly and Company. [1]
It is believed that the new technology will provide not only future early diagnosis of Alzheimer's disease but also possible therapy for Alzheimer's disease. An open international study group (ND.Neuromark.net) has been constituted for arranging scientific information and developing a rational guide for implementing biomarkers into routine ...
NBT allows for easy implementation of new biomarkers, and incorporates an online wiki (the NBTwiki [3]) that aims at facilitating collaboration among NBT users including extensive help and tutorials. The standardised way of data storage and analysis that NBT proposes allow different research projects to merge, compare, or share their data and ...
In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. It may be defined as a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention."
CEA is used as tumor biomarker that can be used for Targeted Radionuclide Therapy. The cT84.66 is a chimeric antibody of murine origin that has been tested in phase I clinical trials with 111-In and 90-Yttrium. [26] [27] 111-In and 90-Y are β- emitters that are used in clinics for imaging and therapy respectively.
Biomarker discovery is a medical term describing the process by which biomarkers are discovered. Many commonly used blood tests in medicine are biomarkers. There is interest in biomarker discovery on the part of the pharmaceutical industry; blood-test or other biomarkers could serve as intermediate markers of disease in clinical trials, and as possible drug targets.
In biomedical contexts, a biomarker, or biological marker, is a measurable indicator of some biological state or condition. Biomarkers are often measured and evaluated using blood, urine, or soft tissues [1] to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. [2]